首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5119896篇
  免费   395691篇
  国内免费   16165篇
耳鼻咽喉   71314篇
儿科学   164792篇
妇产科学   136541篇
基础医学   765128篇
口腔科学   142945篇
临床医学   472254篇
内科学   935240篇
皮肤病学   123023篇
神经病学   424615篇
特种医学   197996篇
外国民族医学   954篇
外科学   767920篇
综合类   143942篇
现状与发展   24篇
一般理论   2885篇
预防医学   420549篇
眼科学   122786篇
药学   365046篇
  27篇
中国医学   14100篇
肿瘤学   259671篇
  2021年   57282篇
  2019年   59649篇
  2018年   77175篇
  2017年   58899篇
  2016年   65347篇
  2015年   77553篇
  2014年   111973篇
  2013年   178051篇
  2012年   147756篇
  2011年   156939篇
  2010年   133666篇
  2009年   132560篇
  2008年   141934篇
  2007年   152774篇
  2006年   159544篇
  2005年   153374篇
  2004年   153811篇
  2003年   143134篇
  2002年   131969篇
  2001年   209829篇
  2000年   206554篇
  1999年   184443篇
  1998年   77240篇
  1997年   71292篇
  1996年   69209篇
  1995年   64697篇
  1994年   58561篇
  1993年   54190篇
  1992年   134764篇
  1991年   129184篇
  1990年   124483篇
  1989年   121091篇
  1988年   111308篇
  1987年   108970篇
  1986年   102655篇
  1985年   99849篇
  1984年   80502篇
  1983年   70745篇
  1982年   52354篇
  1981年   48302篇
  1980年   45152篇
  1979年   69662篇
  1978年   54084篇
  1977年   47815篇
  1976年   44316篇
  1975年   45168篇
  1974年   50410篇
  1973年   48330篇
  1972年   45226篇
  1971年   41951篇
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
961.

Background

Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.

Patients and Methods

We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.

Results

Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.

Conclusions

FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients.  相似文献   
962.
Maternal and Child Health Journal - Background Prenatal substance use screening is recommended. The 4 P’s Plus screener includes questions on perceived problematic substance use in parents...  相似文献   
963.
964.
965.
ObjectiveClinical specialty societies recommend long-acting reversible contraceptives (LARCs) as first-line contraception for adolescent women. We evaluated whether a combined educational and process improvement intervention enhanced LARC placement in primary care within an integrated health care system.MethodsThe intervention included journal clubs, live continuing education, point-of-care guidelines, and new patient materials. We conducted a retrospective cohort study across 3 time periods: baseline (January 2013?September 2015), early implementation (October 2015–March 2016), and full implementation (April 2016–June 2017). The primary outcome was the proportion of LARCs placed by primary care clinicians among women aged 13 to 18 years compared with gynecology clinicians.ResultsKaiser Foundation Health Plan of Colorado cared for approximately 20,000 women aged 13 to 18 years in each calendar quarter between 2013 and 2017. Overall, LARC placement increased from 7.0 per 1000 members per quarter at baseline to 13.0 per 1000 during the full intervention. Primary care clinicians placed 6.2% of all LARCs in 2013, increasing to 32.1% by 2017 (P < .001), including 45.5% of contraceptive implants. Clinicians who attended educational sessions were more likely to adopt LARCs than those who did not (17.9% vs 6.4% respectively, P = .009). Neither overall LARC placement rates (relative risk, 1.9; 95% confidence interval, 0.7?5.6) nor contraceptive implant rates (relative risk, 3.0; 95% confidence interval, 0.9?9.8) increased significantly in clinicians who attended educational activities.ConclusionsThis multimodal intervention was associated with increased LARC placement for adolescent women in primary care. The combination of education and process improvement is a promising strategy to promote clinician behavior change.  相似文献   
966.
967.
968.
969.
李焱  翟凤霞 《陕西中医》2020,(5):660-662
妊娠期间,咳嗽不已,称"妊娠咳嗽",亦称"子嗽",孕妇咳嗽日久未见好转,咳嗽胸痛甚则咳而呕吐,或咳嗽剧烈或久咳不愈,可损伤胎气,导致堕胎、小产。笔者运用六经辨证治疗外感型中表寒里热证子嗽,认为此类患者病在太阳阳明,属于寒热错杂之表寒里热,采用《伤寒论》中方证麻杏甘石汤合止嗽散,使热从外泄,宣发卫气,散寒不助热、解表不伤正,故辨证论治取得了显著的疗效。同时子嗽治疗还需注意健脾固肾安胎,应将顾护胎元贯穿治疗妊娠咳嗽的始终。  相似文献   
970.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号